WEEK 33 – N°1 of “MyList” with * * * stocks: IMMU

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer.

* * * stock
Average yearly return:  +38%

Immunomedics (IMMU) came out with a quarterly loss of $0.30 per share versus a loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.

Strong buy
Strong sell
Only a feeling

If you found this site useful and want to help keep it alive, 

Buy Me A Coffee
We Love Coffee

 to cover the costs and keep the site free of advertisements! Thank you for your support!

Over BillBull

Investment strategist. Never ask me why: 'T.A.' only

Geef een antwoord

Het e-mailadres wordt niet gepubliceerd. Vereiste velden zijn gemarkeerd met *

Deze website gebruikt Akismet om spam te verminderen. Bekijk hoe je reactie-gegevens worden verwerkt.